{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026872","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.337308+00:00","generated_at":"2026-06-21T00:50:07.118216+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Corbus Pharma Q3 net loss $8.8M ($0.07/shr); cash $67M; CRB-601 IND on track for mid-2023","bullets":["Net loss of $8.8M ($0.07 per share) vs $2.2M loss in Q3 2021; prior year included $12.3M tax credit.","Operating expenses decreased to $8.2M from $14.0M, driven by lower clinical trial and manufacturing costs.","Cash and investments $67M; amended debt agreement defers principal payments to September 2023, extending runway.","CRB-601 pre-clinical data at SITC; IND submission on track for mid-2023.","Actively exploring partnerships for CRB-913 (CB1 inverse agonist) for obesity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026872","json":"https://secwatch.observer/filing/0000950170-22-026872.json","markdown":"https://secwatch.observer/filing/0000950170-22-026872.md","text":"https://secwatch.observer/filing/0000950170-22-026872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022026872/0000950170-22-026872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022026872/crbp-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:50:07.118216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"314438ce95776c999dd3ad182dc713beaa306143","claim":"Corbus Pharmaceuticals Holdings, Inc. reported the three months ended September 30, 2022 results: net income net loss of approximately $8.8 million, EPS net loss per diluted share of $0.07.","evidence_excerpt":"The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $0.07, for the three months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022026872/0000950170-22-026872-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"net loss of approximately $8.8 million"},{"label":"EPS","value":"net loss per diluted share of $0.07"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}